Laboratory Expansion to Accelerate Sales in USA

AI SummaryClose X

Cizzle Biotechnology Holdings PLC announced that its North American licensing partner, Cizzle Bio Inc, has entered into a strategic laboratory agreement with BioBridge Global, a healthcare services organization. This agreement will enable BioBridge Global's subsidiary, BBG Advanced Therapies, to become a CLIA-certified laboratory offering Cizzle's CIZ1B Biomarker Blood Test for Lung Cancer to healthcare providers in South Texas, USA, following independent validation. This collaboration is part of Cizzle Bio's strategy to expand national access to its early cancer detection test, building on the initial sales commenced at OmniHealth Diagnostics.

Disclaimer*

UK 100

Latest directors dealings